Modulation of LMNA splicing as a strategy to treat prelamin A diseases.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Investigation

• Publication date

  2016-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI85908PMID 26999604PMCID PMC4811112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.

  2014cited by this paper
• Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome

  2014cited by this paper
• Antagonistic functions of LMNA isoforms in energy expenditure and lifespan

  2014cited by this paper
• When lamins go bad: nuclear structure and disease.

  2013cited by this paper
• Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome

  2012cited by this paper
• Lamin A and lamin C form homodimers and coexist in higher complex forms both in the nucleoplasmic fraction and in the lamina of cultured human cells

  2011cited by this paper
• Splicing-Directed Therapy in a New Mouse Model of Human Accelerated Aging

  2011cited by this paper
• Understanding splicing regulation through RNA splicing maps

  2011cited by this paper
• A conserved splicing mechanism of the LMNA gene controls premature aging.

  2011cited by this paper
• RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

  2010cited by this paper
• Direct Synthesis of Lamin A, Bypassing Prelamin A Processing, Causes Misshapen Nuclei in Fibroblasts but No Detectable Pathology in Mice*

  2010cited by this paper
• Increased expression of the Hutchinson–Gilford progeria syndrome truncated lamin A transcript during cell aging

  2009cited by this paper
• Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.

  2008cited by this paper
• Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging

  2008cited by this paper
• Eliminating the Synthesis of Mature Lamin A Reduces Disease Phenotypes in Mice Carrying a Hutchinson-Gilford Progeria Syndrome Allele*

  2008cited by this paper
• "Laminopathies": a wide spectrum of human diseases.

  2007cited by this paper
• Pre-mRNA Secondary Structures Influence Exon Recognition

  2007cited by this paper
• Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian Organogenesis

  2007cited by this paper
• Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes

  2007cited by this paper
• A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.

  2006cited by this paper
• Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing.

  2006cited by this paper
• Prelamin A and lamin A appear to be dispensable in the nuclear lamina.

  2006cited by this paper
• Lamin A-Dependent Nuclear Defects in Human Aging

  2006cited by this paper
• Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome.

  2006cited by this paper
• Thematic Review Series: Lipid Posttranslational Modifications. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria—new evidence suggesting that protein farnesylation could be important for disease pathogenesis Published, JLR Papers in Press, October 5, 2005. DOI 10.1194/jlr.R500011-JLR200

  2005cited by this paper
• Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.

  2005cited by this paper
• Correction of cellular phenotypes of Hutchinson-Gilford Progeria cells by RNA interference

  2005cited by this paper
• The lethal phenotype of a homozygous nonsense mutation in the lamin A/C gene

  2005cited by this paper
• Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice

  2004cited by this paper
• Lamin A Truncation in Hutchinson-Gilford Progeria

  2003cited by this paper
• Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome

  2003cited by this paper
• Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect

  2002cited by this paper
• Loss of a-Type Lamin Expression Compromises Nuclear Envelope Integrity Leading to Muscular Dystrophy

  1999cited by this paper
• Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing.

  1998cited by this paper
• The processing pathway of prelamin A.

  1994cited by this paper
• Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C.

  1993cited by this paper
• Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina.

  1992cited by this paper
• Maturation of nuclear lamin A involves a specific carboxy‐terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina

  1989cited by this paper
• cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins.

  1986cited by this paper
• Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins

  1986cited by this paper
• The nuclear lamin protein family in higher vertebrates. Identification of quantitatively minor lamin proteins by monoclonal antibodies.

  1986cited by this paper
• Immunocytochemical localization of the major polypeptides of the nuclear pore complex-lamina fraction. Interphase and mitotic distribution

  1978cited by this paper

• A case report with the progression from atrial fibrillation to complete AV block, heart failure and electrical storm.

  2026cites this paper
• Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions

  2025cites this paper
• Selection of specific and efficient siRNAs in new cellular model for Hutchinson-Gilford progeria syndrome therapy

  2025cites this paper
• Prelamin A Does Not Promote Atherosclerosis or Vascular Smooth Muscle Loss

  2025cites this paper
• Integrative Approaches to Myopathies and Muscular Dystrophies: Molecular Mechanisms, Diagnostics, and Future Therapies

  2025cites this paper
• Impact of miR-181a on SIRT1 Expression and Senescence in Hutchinson–Gilford Progeria Syndrome

  2025cites this paper
• The accumulation of progerin underlies the loss of aortic smooth muscle cells in Hutchinson-Gilford progeria syndrome

  2025cites this paper
• Epigenetic regulation of Hutchinson-Gilford progeria syndrome: from molecular mechanisms to targeted interventions

  2025cites this paper
• Precise Progerin Targeting Using RfxCas13d: A Therapeutic Avenue for Hutchinson-Gilford Progeria Syndrome.

  2025cites this paper
• Vascular cell types in progeria: victims or villains?

  2025cites this paper
• ANKRD2 Knockdown as a Therapeutic Strategy in Osteosarcoma: Effects on Proliferation and Drug Response in U2OS and HOS Cells

  2025cites this paper
• Role of lamins in cellular physiology and cancer.

  2025cites this paper
• A deep learning model for characterizing protein-RNA interactions from sequences at single-base resolution

  2025cites this paper
• LMNA-related cardiomyopathy: From molecular pathology to cardiac gene therapy

  2025cites this paper
• Progerin forms an abnormal meshwork and has a dominant-negative effect on the nuclear lamina

  2024cites this paper
• Hutchinson–Gilford progeria syndrome: unraveling the genetic basis, symptoms, and advancements in therapeutic approaches

  2024cites this paper
• The Accumulation of Progerin Underlies the Loss of Aortic Smooth Muscle Cells in Hutchinson-Gilford Progeria Syndrome

  2024cites this paper
• Cardiomyopathy: pathogenesis and therapeutic interventions

  2024influential citation
• Protein isoform-centric therapeutics: expanding targets and increasing specificity

  2024cites this paper
• DNA methylation of the Lamin A/C gene is associated with congenital heart disease

  2024cites this paper
• Navigating Lipodystrophy: Insights from Laminopathies and Beyond

  2024cites this paper
• Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies

  2024cites this paper
• Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives.

  2023cites this paper
• The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations

  2023cites this paper
• mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide–PMO Conjugates

  2023cites this paper
• Prelamin A and ZMPSTE24 in premature and physiological aging

  2023cites this paper
• Hutchinson-Gilford Progeria Syndrome: Cardiovascular Manifestations and Treatment.

  2023cites this paper
• Progerin, an Aberrant Spliced Form of Lamin A, Is a Potential Therapeutic Target for HGPS

  2023cites this paper
• Enhanced Expression of a Novel Lamin A/C Splice Variant in IPF Lung.

  2023cites this paper
• Progeria: a perspective on potential drug targets and treatment strategies

  2022cites this paper
• The exon-skipping oligonucleotide, KitStop, depletes tissue-resident mast cells in vivo to ameliorate anaphylaxis

  2022cites this paper
• Nuclear envelope morphology change upon repetitive treatment with modified antisense oligonucleotides targeting Hutchinson-Gilford Progeria Syndrome

  2022cites this paper
• Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation

  2022cites this paper
• Silicon Nanoneedle-Induced Nuclear Deformation: Implications for Human Somatic and Stem Cell Nuclear Mechanics.

  2022cites this paper
• Hutchinson-Gilford Progeria Syndrome: A Literature Review

  2022cites this paper
• The macromolecular machinery of the nucleus in the senescence process

  2022cites this paper
• Vascular smooth muscle cell aging: Insights from Hutchinson-Gilford progeria syndrome.

  2022cites this paper
• Mechanotranduction Pathways in the Regulation of Mitochondrial Homeostasis in Cardiomyocytes

  2021cites this paper
• Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach.

  2021cites this paper
• Splice-inhibition therapy targets progeria

  2021cites this paper
• Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson–Gilford progeria syndrome

  2021cites this paper
• Regulation of splicing in cardiovascular disease

  2021cites this paper
• Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models

  2021cites this paper
• Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy

  2021cites this paper
• Nuclear membrane ruptures underlie the vascular pathology in a mouse model of Hutchinson-Gilford progeria syndrome

  2021cites this paper
• Hutchinson-Gilford Progeria Syndrome (Hgps) And Application Of Gene Therapy Based Crispr/Cas Technology As A Promising Innovative Treatment Approach.

  2021cites this paper
• Preclinical Advances of Therapies for Laminopathies

  2021cites this paper
• Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome

  2021cites this paper
• Abolishing the prelamin A ZMPSTE24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice

  2021cites this paper
• Clinical Genetics and Genomics of Aging

  2020cites this paper
• Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson–Gilford progeria syndrome

  2020cites this paper
• Premature Vascular Aging with Features of Plaque Vulnerability in an Atheroprone Mouse Model of Hutchinson–Gilford Progeria Syndrome with Ldlr Deficiency

  2020cites this paper
• Progress and trends in the development of therapies for Hutchinson–Gilford progeria syndrome

  2020cites this paper
• Hereditary syndromes with signs of premature aging

  2020cites this paper
• Metabolic Dysfunction in Hutchinson–Gilford Progeria Syndrome

  2020cites this paper
• In Vivo Base Editing Rescues Hutchinson-Gilford Progeria Syndrome in Mice

  2020cites this paper
• Molecular Basis of Progeroid Diseases

  2020cites this paper
• Nuclear membrane ruptures, cell death, and tissue damage in the setting of nuclear lamin deficiencies

  2020cites this paper
• Premature aging disorders: A clinical and genetic compendium

  2020cites this paper
• Targeting senescent cells to attenuate cardiovascular disease progression.

  2020cites this paper
• RNA therapeutics: Identification of novel targets leading to drug discovery

  2019influential citation
• Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy Treatment

  2019cites this paper
• Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome

  2019cites this paper
• A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes

  2019cites this paper
• Lamin A/C Cardiomyopathy: Implications for Treatment

  2019cites this paper
• Antisense-mediated splice intervention to treat human disease: the odyssey continues

  2019cites this paper
• Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers.

  2018cites this paper
• Nuclear Lamin Protein C Is Linked to Lineage-Specific, Whole-Cell Mechanical Properties

  2018cites this paper
• Aging in the Cardiovascular System: Lessons from Hutchinson-Gilford Progeria Syndrome.

  2018cites this paper
• The Emerging Role of Lamin C as an Important LMNA Isoform in Mechanophenotype

  2018cites this paper
• An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome

  2018cites this paper
• Mechanisms of vascular aging: What can we learn from Hutchinson-Gilford progeria syndrome?

  2018cites this paper
• Lamins and Lamin-Associated Proteins in Gastrointestinal Health and Disease.

  2018cites this paper
• Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.

  2018cites this paper
• A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation

  2018cites this paper
• Vascular Smooth Muscle–Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome

  2018cites this paper
• Mecanismos de envejecimiento vascular: ¿Qué podemos aprender del síndrome de progeria de Hutchinson-Gilford?

  2018cites this paper
• Progeria and accelerated cardiovascular aging

  2018cites this paper
• Nuclear Lamin Protein C Is Linked to Lineage-Specific, Whole-Cell Mechanical Properties

  2018cites this paper
• Hutchinson-Gilford Progeria Syndrome Vascular Pathology: A Focused Review

  2018cites this paper
• Non-invasive monitoring of alternative splicing outcomes to identify candidate therapies for myotonic dystrophy type 1

  2018cites this paper
• The Pathogenesis and Therapies of Striated Muscle Laminopathies

  2018cites this paper
• Disrupting the LINC complex in smooth muscle cells reduces aortic disease in a mouse model of Hutchinson-Gilford progeria syndrome

  2018cites this paper
• Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies

  2018cites this paper
• Correction of a Splicing Mutation Affecting an Unverricht-Lundborg Disease Patient by Antisense Therapy

  2018cites this paper
• Permanently Farnesylated Prelamin A, Progeria, and Atherosclerosis

  2018cites this paper
• Upregulation of the aging related LMNA splice variant progerin in dilated cardiomyopathy

  2018cites this paper
• Current insights into LMNA cardiomyopathies: Existing models and missing LINCs

  2017cites this paper
• Recent Advances in Understanding and Managing Cardiomyopathy

  2017cites this paper
• Intermediate filament proteins of digestive organs: physiology and pathophysiology

  2017cites this paper
• Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.

  2017cites this paper
• Lamin and the heart

  2017cites this paper
• MG132‐induced progerin clearance is mediated by autophagy activation and splicing regulation

  2017cites this paper
• Intermediate filament proteins of digestive organs: physiology and pathophysiology.

  2017cites this paper
• Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations.

  2017cites this paper
• The effect of hypoxia on alternative splicing in prostate cancer cell lines

  2017cites this paper
• Seeking a Cure for One of the Rarest Diseases: Progeria

  2016cites this paper
• Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability.

  2016cites this paper
• Antisense-Based Progerin Downregulation in HGPS-Like Patients’ Cells

  2016cites this paper
• Splice-switching antisense oligonucleotides as therapeutic drugs

  2016cites this paper